Accelerating Time to Pathogen-adapted Antibiotic Treatment through Culture-independent Antimicrobial Susceptibility Testing in Patients Suffering from Sepsis. (4th October 2017)

• Record Type: Journal Article
• Authors: Karrasch, Matthias; Bender, Marco; Geraci, Jennifer; Brunkhorst, Frank; Löffler, Bettina
• Is Part Of: Open forum infectious diseases. Volume 4(2017)Supplement 1
• Page Start: S615
• Page End: S615
• Publication Date: 2017-10-04
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofx163.1619
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: Accurate and fast pathogen identification and consecutive antimicrobial susceptibility testing (AST) is of vital importance for patient outcome in patients suffering from sepsis. Methods: The Accelerate Pheno™ system is a new, fully automated, culture-independent diagnostic method for both pathogen identification (ID) and antimicrobial susceptibility testing (AST). We analyzed positive blood cultures from critically ill patients with new onset of sepsis according to the new sepsis guidelines, using both conventional standard methods (VITEK, MALDI-TOF) and Accelerate Pheno™ system. ID/AST results of the Accelerate Pheno™ system were not reported to treating physicians as part of our internal evaluation process. Results: Accelerate Pheno™ system correctly detected 74 pathogens [Gram-negative (GN) ( n = 27), Gram-positive (GP) ( n = 47)] straight out of 84 positive blood culture bottles. Gram-negative (GN) pathogens were identified as E. coli ( n = 15; concordance rate 100%), K. pneumonia ( n = 7; 71, 4 %), S. marcescens ( n = 3; 100%), E. cloacae (n = 2; 50%), P. mirabilis ( n = 1; 100%) and P. aeruginosa ( n = 1; 33%). Gram-positive pathogens were identified as CNS ( n = 24; 82, 6%), S. aureus ( n = 15; 88, 2%), E. faecium ( n = 6; 100%) and E. faecalis ( n = 2; 100%). The Accelerate Pheno™ system generated a GN-AST result in 70, 4 % (19 of 27 samples) and a GP-AST result in 61, 7 % (29 of 47 samples) when compared with routine AST. Growth control, analysis and mechanical failure led to reduced results in comparison to conventional ID/AST. Accelerate Pheno TM delivered correct MIC-results for most of the panel antibiotics [e.g., meropenem: 83, 3%, gentamicin: 88, 9%, ertapenem: 100%]. Conclusion: The use of the Accelerate Pheno™ system significantly improved time-to-ID/AST and would have led to a reduced time-to-treatment in patients suffering from sepsis if results would have been reported. The system currently has some weakness in the detection of polymicrobial and streptococcal infections but due to the short hands-on-time, culture-independence and fast generation of results, it represents a promising new diagnostic method for the consecutive antibiotic treatment of septic patients. Disclosures: All authors: No reported disclosures.